Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 2/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HRH1 | P35367 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL524534 | 0.94 | HDAC1 (0.39) | RBP4ITGB3ITGA2BHDAC1KDM4E | |
| Trifluoroacetic Acid SCHEMBL3468332 | 0.87 | KDM4E (0.42) | RBP4PDK2KDM4EALDH1A1 | |
| SCHEMBL20854266 | 0.83 | F13A1 (0.39) | KDM4ELMNASIGMAR1TP53ALDH1A1 | |
| SCHEMBL3468335 | 0.83 | PDK2 (0.40) | RBP4PDK2KDM4EALDH1A1 | |
| SCHEMBL10102483 | 0.82 | ALDH1A1 (0.40) | RBP4ITGB3ITGA2BHDAC1KDM4E | |
| SCHEMBL19384145 | 0.82 | HDAC1 (0.38) | RBP4ITGB3ITGA2BHDAC1KDM4E | |
| SCHEMBL3466840 | 0.80 | KDM4E (0.45) | RBP4KDM4ELMNAALDH1A1HRH1 | |
| SCHEMBL19384156 | 0.79 | CTSL (0.38) | RBP4ITGB3ITGA2BHDAC1KDM4E | |
| Trifluoroacetic Acid SCHEMBL523117 | 0.79 | LPAR1 (0.37) | — | |
| SCHEMBL19384155 | 0.73 | HTR1D (0.56) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8969350-B2 | Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredient | ASTRAZENECA AB (SE) | 2015-03-03 | — | — | US | disclosed |
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | ASTRAZENECA UK LIMITED (GB) | 2012-02-02 | — | — | US | disclosed |
| EP-2379174-A1 | PHARMACEUTICAL PRODUCT COMPRISING A P38 KINASE INHIBITOR AND A SECOND ACTIVE INGREDIENT | AstraZeneca AB (SE) | 2011-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028941-A1 | Pharmaceutical Product Comprising a P38 Kinase Inhibitor and a Second Active Ingredient | NR3C2, ARRB1, GRK4 | RBP4 2022/4885ITGB3 729/4885ITGA2B 408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.